Amgen’s first quarter 2026 total revenues increased 6% to $8.6 billion year over year, according to the Thousand Oaks-based biotech giant’s first quarter earnings report released April 30. Product sales grew 4% compared to first quarter 2025, driven by 9% volume growth, partially offset by 2% lower net selling price and 2% from lower inventory levels, the report says. Sixteen products…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
